BREAST CANCER RESISTANCE PROTEIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 337

TABLE 12.2. Summary of Investigations Measuring ABCG2 Expression or Function in Leukemia
Author Method a

Cancer Samples Conclusion

Ross et al. 149 Leukemia RT-PCR 20 AML samples 1

ALL sample

Relatively high ABCG2 levels in seven samples (33%). No
correlation with ABCB1 expression.

Sargent et al. 208 AML IHC: BXP-34

antibody

Blast cells from 20
patients with AML

Six of 22 (27%) samples had > 10% of cells positive.

van Der Kolk
et al. 152

AML FC: BXP-21,

mitoxantrone
transport

20 paired de novo and
relapsed/refractory
AML

Low levels of ABCG2 expression in AML. No up-regulation
of ABCG2 expression or activity at relapse. High ABCG2
expression with immature phenotype.

Sauerbrey et al. 160 Childhood ALL RT-PCR 47 de novo samples 20

relapsed samples

Lower ABCG2 expression in T-cell lineages. No correlation
between expression and response.

Abbott et al. 154

AML RT-PCR 40 de novo samples High levels of ABCG2 uncommon in AML, but high levels

may be due to small subset of cells. No correlation between
ABCG2 expression and response.

Steinbach et al. 155 Childhood AML RT-PCR 59 untreated AML

9 relapsed cases

Median ABCG2 levels 10-fold higher in patients who did not
achieve remission compared to responders. ABCG2 levels
higher in first relapse than at diagnosis. Expression related
to prognosis.

van den
Huevel-Eibrink
et al. 209

AML RT-PCR 20 paired de novo and

relapsed/refractory
AML samples

ABCG2 levels higher in relapsed/refractory samples than at
diagnosis. Significant coexpression of ABCG2 and ABCB1.

( Continued )